Xenon reports Q2 net loss $47.5M; XEN1101 MDD trial fully enrolled with data expected late Nov-Dec

Xenon Pharmaceuticals Inc.

2023-Q2 EPS reported -$1.36

Q2 net loss $47.5M vs $31.2M YoY; R&D expenses doubled to $44.0M on XEN1101 Phase 3 and MDD trials.
Cash $652.2M (down from $720.8M); sufficient to fund operations into 2026.
Last patient enrolled in XEN1101 Phase 2 X-NOVA MDD trial; topline data expected late Nov to mid-Dec 2023.
Phase 3 epilepsy trials X-TOLE2/3 and X-ACKT continue; partnered NBI-921352 Phase 2 data expected Q4 2023.
Webinar on MDD mechanism and X-NOVA design scheduled for mid-September.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenon Pharmaceuticals Inc. reported financial results for three and six months ended June 30, 2023.

Period: three and six months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 9, 2023, Xenon Pharmaceuticals Inc. (the "Company") announced via press release the Company's financial results for the three and six months ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.